文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症重症综合管理与镇静镇痛

托珠单抗与巴瑞替尼在COVID-19肺炎伴低氧血症住院患者中的比较:一项多中心回顾性队列研究

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2022-05-11
一句话结论在同时接受地塞米松的COVID-19肺炎伴低氧血症住院患者中,托珠单抗与巴瑞替尼治疗的出院结局似乎相似。

该多中心回顾性队列研究纳入威斯康星州7家急性病医院收治的COVID-19、低氧血症且Pao2/Fio2≤300 mmHg、接受托珠单抗或巴瑞替尼的患者,按实际用药分为托珠单抗组(194例)和巴瑞替尼组(188例),所有患者均接受地塞米松。主要终点为60天内无机械通气存活出院,采用逻辑回归评估,未校正、多因素校正及倾向性评分匹配分析均显示两组成功出院概率在数量上相似。住院时长、血栓栓塞事件发生率及医院获得性感染发生率在两组也相似。作者认为在接受地塞米松的患者中,两种治疗结局似乎相似。

要点

  • 纳入382例COVID-19肺炎伴低氧血症且Pao2/Fio2≤300 mmHg的住院患者,托珠单抗组194例、巴瑞替尼组188例,全部接受地塞米松。
  • 在380例可随访患者中,60天内无机械通气存活出院概率在未校正、多因素校正和倾向性评分匹配分析中两组均数量相似。
  • 住院时长、血栓栓塞事件发生率、医院获得性感染发生率在两组均相似。
  • 2例失访,最终分析380例。

适用人群与场景

  • 威斯康星州7家急性病医院收治的COVID-19住院患者,伴低氧血症且Pao2/Fio2≤300 mmHg,接受托珠单抗或巴瑞替尼治疗。

诊断标准与关键阈值

  • 低氧血症且Pao2/Fio2≤300 mmHg。

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究;7家急性病医院;纳入382例,托珠单抗组194例、巴瑞替尼组188例;全部接受地塞米松;2例失访。
  • 主要终点:60天内无机械通气存活出院,采用逻辑回归评估;在380例中,未校正、多因素校正及倾向性评分匹配分析均显示两组成功出院概率数量相似。
  • 次要终点:住院时长、血栓栓塞事件发生率、医院获得性感染发生率在两组均相似。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受地塞米松的COVID-19肺炎伴低氧血症住院患者中,托珠单抗或巴瑞替尼治疗似乎产生相似结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectiveness of tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia.

DESIGN: Retrospective cohort study.

SETTING: Seven inpatient acute-care hospitals in Wisconsin.

PARTICIPANTS: Patients hospitalized with COVID-19, hypoxemia, and Pao2-to-Fio2 ratio less than or equal to 300 mm Hg, who received either tocilizumab or baricitinib.

INTERVENTIONS: Electronic chart review.

MEASUREMENTS AND MAIN RESULTS: Patients were divided into tocilizumab and baricitinib cohorts based on actual medication received. The primary outcome was hospital discharge alive and free from mechanical ventilation within 60 days, assessed by logistic regression. Three hundred eighty-two patients were included: 194 in the tocilizumab cohort and 188 in the baricitinib cohort. Most baseline characteristics in the two cohorts were similar. All patients received dexamethasone. Two patients were lost to follow-up. In the remaining 380 patients, probability of successful discharge in the two cohorts was quantitatively similar in unadjusted, multivariate-adjusted, and propensity score-matched analyses. Hospital length of stay, rates of thromboembolic events, and rates of hospital-acquired infections were all similar in the two cohorts.

CONCLUSIONS: In patients hospitalized with COVID-19 pneumonia and hypoxemia who receive dexamethasone, treatment with tocilizumab or baricitinib appears to result in similar outcomes.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Roddy J, Wells D, Schenck K, et al. Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. Crit Care Explor. 2022. PMID: 35783551. doi:10.1097/CCE.0000000000000702

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。